![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, August 06, 2013 9:29:38 AM
LymPro has enormous potential and Gerald has indicated that its full speed ahead. They are going to add new talent and expertise and now have an solid relationship with Becton Dickinson to commercialize LymPro (what you need to understand is that Amarantus will retain full rights meaning they wont have to share the revenues or pay royalties at this time).
MANF programs will now be accelerated as they have identified Orphan indications to speed the process. It sounds very promising that their will be an IND sometime next year for one Orphan indication. Also, they have purchased a Phase IIb compound that will be developed within a year (for Parkinsons too).
Lastly, the capability to obtain the necessary funding/financing will now only increase as the company hits their milestones (I would not want any dilutive deals to occur down at these prices....we had enough dilution already).
Long term bulls will be happy to hear the positive news/update. The S/T flippers and quick buck artists will more than likely leave (and that's a good thing).
Glidelogic Corp. Announces Revolutionary AI-Generated Content Copyright Protection Solution • GDLG • Jul 26, 2024 12:30 PM
Southern Silver Files NI43-101 Technical Report for its Updated Preliminary Economic Assessment for the Cerro Las Minitas Project • SSV • Jul 25, 2024 8:00 AM
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM